January 4, 2018 / 12:34 PM / in 6 months

BRIEF-Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese

Jan 4 (Reuters) - Akebia Therapeutics Inc:

* AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA ASSOCIATED WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE

* DATA CONSISTENT WITH FINDINGS FROM PREVIOUS STUDIES​

* ‍PHASE 3 STUDY OF NON-DIALYSIS PATIENTS IN JAPAN ONGOING; PHASE 3 STUDIES OF DIALYSIS PATIENTS TO BEGIN IN 2018​

* STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT OBSERVED IN VADADUSTAT GROUP 150 MG (P = 0.0004) COMPARED TO PLACEBO​

* STATISTICALLY SIGNIFICANT IMPROVEMENTS ALSO OBSERVED IN VADADUSTAT GROUPS 300 MG(P<0.0001), 600 MG(P< 0.0001),COMPARED TO PLACEBO​

* SERIOUS ADVERSE EVENTS WERE CONSISTENT WITH PRIOR STUDIES

* NO DEATHS WERE REPORTED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below